Cardiovascular Systems (NASDAQ:CSII) announced its quarterly earnings results on Tuesday. The medical device company reported $0.04 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.04, Fidelity Earnings reports. The business had revenue of $68.23 million for the quarter, compared to analysts’ expectations of $66.04 million. Cardiovascular Systems had a return on equity of 1.47% and a net margin of 0.84%. Cardiovascular Systems updated its FY 2020 guidance to EPS.
NASDAQ CSII traded up $1.22 on Wednesday, reaching $44.85. 523,295 shares of the stock traded hands, compared to its average volume of 387,618. The stock’s fifty day moving average price is $43.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.78 and a current ratio of 4.25. The company has a market capitalization of $1.55 billion, a P/E ratio of 897.00 and a beta of 1.77. Cardiovascular Systems has a 12 month low of $24.84 and a 12 month high of $49.37.
A number of brokerages recently issued reports on CSII. Zacks Investment Research raised Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a report on Thursday, April 18th. Stifel Nicolaus lowered Cardiovascular Systems from a “buy” rating to a “hold” rating and increased their price objective for the stock from $41.00 to $45.00 in a report on Tuesday, July 16th. They noted that the move was a valuation call. Needham & Company LLC reissued a “hold” rating on shares of Cardiovascular Systems in a report on Thursday, May 2nd. Bank of America lowered Cardiovascular Systems from a “buy” rating to an “underperform” rating and set a $42.00 price objective for the company. in a report on Thursday, April 11th. They noted that the move was a valuation call. Finally, BidaskClub lowered Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Friday, August 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $42.00.
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Featured Article: Understanding Options Trading
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.